OQROGet OQRO Pro
Insider trade

Alnylam Pharmaceuticals (ALNY)EVP Chief R&D sold ~$47K

Pushkal Garg, EVP Chief R&D at Alnylam Pharmaceuticals, sold ~$47K of Alnylam Pharmaceuticals shares.

~$47K
Approx. value · 103 sh @ $451.99
23K
Holds after · shares reported
Traded
Aug 18, 2025
Filed
Aug 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 12, 2025CongressDisclosed sale of ALNY — reported range $15,001 - $50,000
  2. Aug 14, 2025Insider · 1 personInsiders: 11 sales (~$13.7M)
  3. Aug 18, 2025 · this disclosureInsiderOfficer sold ~$47K of ALNY shares in the open market

What came next

  1. Aug 18, 2025Insider · 6 peopleInsiders: 40 sales (~$11.1M)
  2. Aug 19, 2025Insider · 1 personInsiders: 6 sales (~$667K)
  3. Aug 29, 2025Insider · 1 personInsiders: 6 sales (~$1.6M)
  4. Sep 9, 2025Insider · 1 personInsiders: 15 sales (~$7.7M)
  5. Sep 12, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  6. Sep 30, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  7. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  8. Dec 2, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 2, 2025, Michael W. Bonney and Carolyn Bertozzi, Ph.D. provided notice of each of their resignations from the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), effective on the same date.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alnylam Pharmaceuticals

For Alnylam Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 24 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALNY page.

Other recent filings by Pushkal Garg, EVP Chief R&D

The full history of Pushkal Garg, EVP Chief R&D is on the profile page.

How this filing works

Other disclosures at Alnylam Pharmaceuticals

Everything OQRO holds on this company is on its ALNY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data